- Home
- MHUA vs LPTX Comparison
MHUA vs LPTX Comparison
Compare MHUA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- LPTX
- Stock Information
- Founded
- MHUA 1990
- LPTX 2011
- Country
- MHUA China
- LPTX United States
- Employees
- MHUA N/A
- LPTX N/A
- Industry
- MHUA Medical Specialities
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MHUA Health Care
- LPTX Health Care
- Exchange
- MHUA Nasdaq
- LPTX Nasdaq
- Market Cap
- MHUA 11.8M
- LPTX 11.1M
- IPO Year
- MHUA 2022
- LPTX N/A
- Fundamental
- Price
- MHUA $0.42
- LPTX $0.31
- Analyst Decision
- MHUA
- LPTX Hold
- Analyst Count
- MHUA 0
- LPTX 1
- Target Price
- MHUA N/A
- LPTX N/A
- AVG Volume (30 Days)
- MHUA 147.2K
- LPTX 802.0K
- Earning Date
- MHUA 09-19-2025
- LPTX 11-12-2025
- Dividend Yield
- MHUA N/A
- LPTX N/A
- EPS Growth
- MHUA N/A
- LPTX N/A
- EPS
- MHUA 0.40
- LPTX N/A
- Revenue
- MHUA $96,909,642.00
- LPTX N/A
- Revenue This Year
- MHUA N/A
- LPTX N/A
- Revenue Next Year
- MHUA N/A
- LPTX N/A
- P/E Ratio
- MHUA $1.22
- LPTX N/A
- Revenue Growth
- MHUA N/A
- LPTX N/A
- 52 Week Low
- MHUA $0.25
- LPTX $0.22
- 52 Week High
- MHUA $1.24
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MHUA 52.84
- LPTX 54.59
- Support Level
- MHUA $0.39
- LPTX $0.28
- Resistance Level
- MHUA $0.50
- LPTX $0.29
- Average True Range (ATR)
- MHUA 0.04
- LPTX 0.02
- MACD
- MHUA 0.00
- LPTX 0.00
- Stochastic Oscillator
- MHUA 49.53
- LPTX 90.14
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.